Core Insights - Aptar Group has been in operation for approximately 80 years and has been publicly traded for 35 years, with the pharmaceutical segment contributing nearly 70% of EBITDA [2]. Company Overview - The company focuses on proprietary drug delivery devices, primarily for nasal and inhalation applications, as well as ophthalmic and dermal delivery systems [2]. - The beauty and closure segments also contribute to the company's portfolio, targeting demographics such as the aging population and health-conscious consumers [3]. Market Focus - Aptar Group's pharmaceutical applications are mainly aimed at chronic disease treatments, including asthma, COPD, and allergic rhinitis, which require daily medication [3]. - The company organizes its operations into three reporting segments but manages its business primarily through technology platforms [3].